Percutaneous devices for left atrial appendage occlusion: A contemporary review

Table 2 Antithrombotic therapy regimens following left atrial appendage occlusion

Study/reference	Regimen
PROTECT AF trial[48-50]	Warfarin for 45 d followed by aspirin and clopidogrel for 6 mo, then aspirin indefinitely
PREVAIL trial[51]	Warfarin for 45 d followed by aspirin and clopidogrel for 6 mo, then aspirin indefinitely
EWOLUTION registry[56]	warfarin in 16%, NOAC in 11%, DAPT in 60%, SAPT in 7%, and no therapy in 6%
RELEXAO registry[72]	OACs in 28.8%, SAPT in 36.2%, DAPT in 23.2%, OACs plus DAPT in 4.3%, and no therapy in 7.5%.
ASAP trial[58]	DAPT for 6 mo followed by aspirin indefinitely
EHRA/EAPCI expert consensus[75]	DAPT for 1 to 6 mo followed by aspirin indefinitely

OAC: Oral anticoagulant; NOAC: Non-vitamin K oral anticoagulant; SAPT: Single antiplatelet; DAPT: Dual antiplatelet; EHRA/EAPCI: European Heart Rhythm Association/European Association of Percutaneous Cardiovascular Interventions.